Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, and Sarrazin MSV.

Primary objective: To compare the efficacy and safety outcomes in obese patients who initiated apixaban, rivaroxaban, dabigatran with warfarin Secondary objective: To compare outcomes in patients with morbid obesity